New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
05:37 EDTHTWR, THORThoratec downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Thoratec to Neutral citing the weaker LVAD market and limited visibility following the company's Q2 results. The firm lowered its price target for shares to $28 from $38. Goldman keeps a Sell rating on peer HeartWare (HTWR) and lowered its price target on the name to $73 from $75.
News For THOR;HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for THOR;HTWR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use